City of Hope | Strategic Alliance Partners

September 28, 2024

Saro H. Armenian, DO, MPH, raises awareness for childhood-related cancer interventions during Childhood Cancer Awareness Month.

September 26, 2024

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.

September 25, 2024

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

September 25, 2024

Saro H. Armenian, DO, MPH, discusses the difficulties that patients face when transitioning from pediatric to adult cancer care, highlighting unmet needs.

September 23, 2024

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.

September 19, 2024

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

September 18, 2024

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

September 18, 2024

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

September 11, 2024

Alexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.

September 11, 2024

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

September 11, 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

September 11, 2024

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

September 11, 2024

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

September 05, 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

September 04, 2024

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

September 04, 2024

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

September 02, 2024

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

August 30, 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

August 29, 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

August 29, 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.